Calcium channel drugs and uses

Details Calcium channel drugs and uses Calcium channel drugs and uses

2006-09-05

2006-09-05

Wang, Andrew (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S179000, C560S189000, C540S491000, C546S321000, C514S211070, C514S356000, C544S129000, C544S358000

Reexamination Certificate

active

07101909

ABSTRACT:
Novel multibinding compounds are disclosed. The compounds of this invention comprise 2–10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca++channel, thereby modulating the biological activities thereof.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4532248 (1985-07-01), Franckowiak et al.
patent: 4725597 (1988-02-01), Devlin et al.
patent: 4771057 (1988-09-01), Knaus et al.
patent: 4808605 (1989-02-01), Branca et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5120730 (1992-06-01), Pifferi et al.
patent: 5378698 (1995-01-01), Yamamori et al.
patent: 5462936 (1995-10-01), Yamamori et al.
patent: 5463564 (1995-10-01), Agrafiotis et al.
patent: 5571827 (1996-11-01), Barberich et al.
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5686495 (1997-11-01), Goldin et al.
patent: 5723618 (1998-03-01), Leung-Toung et al.
patent: 5767131 (1998-06-01), Gluchowski et al.
patent: 5846839 (1998-12-01), Gallop et al.
patent: 5891643 (1999-04-01), Fesik et al.
patent: 6420560 (2002-07-01), Numerof et al.
patent: 6897305 (2005-05-01), Ji et al.
patent: 1179342 (1984-12-01), None
patent: 2240325 (1998-06-01), None
patent: 0 052 300 (1982-05-01), None
patent: 0 052 300 (1982-05-01), None
patent: 0 122 488 (1984-10-01), None
patent: 0 266 549 (1988-05-01), None
patent: WO 92/05802 (1992-04-01), None
patent: WO 93/06121 (1993-04-01), None
patent: WO 96/33972 (1996-10-01), None
patent: WO 97/21445 (1997-06-01), None
patent: WO 98/00439 (1998-01-01), None
patent: WO 98/34948 (1998-08-01), None
patent: WO 99/63992 (1999-12-01), None
Wiltshire, H. R. et al. “Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man” Xenobiotica 1997, 27(6), 539-556.
Alker et al., “Formation, Synthetic Utility and Structure Elucidation of a 2-Bromomethyl 1,4-Dihydropyridine”, Tetrahedron Letters, vol. 31, No. 10, pp. 1479-1482 (1990).
Arrowsmith et al., “Long-Acting Dihydropyridine Calcium Antagonists. 1.2-Alkoxymethyl Derivatives Incorporating Basic Substituents”, J. Med. Chem. 29: 1696-1702 (1986).
Balboni et al., “Calcium Antagonists: Vinylogues and bivalent ligands related to nifedipine”, Pharmazie 43, pp. 318-320 (1988).
Bezprozvanny et al., “Voltage-Dependent Blockate of Diverse Types of Voltage-Gated Ca2+Channels Expressed inXenopus Oocytesby the Ca2+Channel Antagonist Mibefradl (Ro 40-5967)”, Molec. Pharmacol. 48 pp. 540-549 (1995).
Bossert et al., “4-Aryldihydropyridines, a New Class of Highly Active Calcium Antagonists”, Angew. Chem. Int. Ed. 20: 762-769 (1981).
Brenner et al., “Encoded combinatorial chemistry”, Proc. Natl. Acad. Sci., USA, 89: pp 5381-5383 (1992).
Brittain et al., “Relaxation of K+Contracted Rabbit Aortic Strips Implies Calcium Channel Blockade”, Physiologist, vol. 28, No. 4: 325 (1985).
Cremers et al., “Effects of the Novel T-Type Calcium Channel Antagonist Mibefradil on Human Myocardial Contractilty in Comparison with Nifedipine and Verapamil”, J. Cardiovasc. Pharmacol. 29: 692-696 (1997).
Cross et al., “Selective Class III Antiarrhythmic Agents. 1. Bis(arylalkyl)amines”, J. Med. Chem. 33(4);1151-1155 (1990).
Denyer et al., “HTS Approaches to Voltage-Gated Ion Channel Drug Discovery”, Drug Discovery Today, vol. 3, No. 7, pp. 323-332 (1998).
Eltze et al., “Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-Dihydropyridine Calcium Channel Antagonists”, Chirality, 2:233-240 (1990).
Gordeev et al., “A General and Efficient Solid Phase Synthesis of Quinazoline-2,4-diones”, Tetrahedron Letters, vol. 38, No. 10, pp. 1729-1732 (1997).
Gordeev et al., “Approaches to Combinatorial Synthesis of Heterocycles: A Solid Phase Synthesis of 1,4-Dihydropyridines”, J. Org. Chem. 81:924-928 (1996).
Hess et al., “Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists”, Nature 311:538-544 (1984).
Hockerman et al., “Molecular Determination of Drug Binding and Action on L-Type Calcium Channels”, Annu. Rev. Pharmacol. Toxicol. 37:361-396 (1997).
Inoue et al., “Synthesis of Halogen-Substituted 1,5-Benzothiazepine Derivatives and Their Vasodilating and Hypotensive Activities”, J. Med. Chem., vol. 34, No. 2, pp. 675-687 (1991).
Joslyn et al., “Dimeric 1,4-Dihydropyridines as Calcium Channel Antagonists”, J. Med. Chem, vol. 31, No. 8, pp. 1489-1492 (1988).
Kenny et al., “The Application of High-throughput Screening to Novel Lead Discovery” Progress in Drug Research. vol. 15, pp. 245-269 (1998).
Kokubun et al., “Studies on Ca Channels in Intact Cardiac Cells:Voltage-Dependent Effects and Cooperative Interactions of Dihydropyridine Enantiomers”, Molec. Pharmacol. 30: 571-584 (1986).
Liang et al., “Parallel synthesis and screening of a solid phase carbohydrate library”, Science, 274, pp. 1520-1522 (1996).
Nagao et al., “Studies on a New 1,5-Benzothiazepine Derivative (CRD-401). IV. Coronary Vasodilating Effect and Structure-Activity Relationship”, Chem. Pharm. Bull., vol. 21, No. 1, pp. 92-97 (1973).
Osterrieder et al., “In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+Channel Blocker with Potent Vasodilator but Weak Inotropic Action”, J. Cardiovas. Pharmacol. 13:754-759 (1989).
PD-029361. The Investigational Drugs Database Drug Report—2 pages (2004).
Portoghese, P. S., “The Role of Concepts in Structure-Activity Relationship Studies of Oploid Ligands”, J. Med. Chem. vol. 35, No. 11:pp. 1927-1937 (1992).
Rampe et al., “New synthetic ligands for L-type voltage-gated calcium channels”, Prog. Drug. Res. 40:191-231 (1993).
Rovnyak et al., “Dihydropyrimidine Calcium Channel Blockers. 4, Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Agents”, J. Med. Chem. 35:3254-3263 (1992).
Shuker et al., “Discovering High-Affinity Ligands for Proteins, SAR by NMR”, Science, 274:1531-1534 (1996).
Süli-Vargha et al., “Decomposition of N-(2-Chloroethyl)-N-nitrosocarbamoyl Amino Acid Amides”, J. Med. Chem., vol. 31, pp. 1492-1495 (1988).
Tokuma et al., Stereoselective pharmacokinetics of dihydropyridine calcium antagonists, J. Chromatography A, 694:181-193 (1995).
Van Albada et al., Accession No. 1995:776400; CAPLUS database on STN (Inorg. Chem. (1995), 34(19), pp. 4910-4917; Abstract only.
Yuen et al., “Synthesis and Structure-Activity Relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type Calcium Channel Blockers”, Bioorg. and Med Chem. Letters, vol. 8, pp. 2415-2418 (1996).
Zeng et al., “Automated analytical/preparative high performance liquid chromatography-mass spectrometry system for the rapid characterization and purification of compound libraries”, J. Chrom. A, 794, pp. 3-13 (1998).

Affiliated with

Also associated with

Rating

Calcium channel drugs and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Calcium channel drugs and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium channel drugs and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3528165